SRD5A2 gene polymorphisms and the risk of prostate cancer: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 7, 2003, Pages 618-624

  Ntais, Christos ^a   Polycarpou, Anastasia ^a   Ioannidis, John P A ^a,b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5BETA REDUCTASE;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; GENE; GENETICS; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE; SRD5A2 GENE;

BIOLOGICAL MARKERS; CHOLESTENONE 5 ALPHA-REDUCTASE; GENOTYPE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0041846618     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst., 88: 1118-1126, 1996.
2. Makridakis, N. M., and Reichardt, J. K. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 23: 24-29, 2001.
3. Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato McGinley, J., Griffin, J. E., Francke, U., Wilson, J. D., and Russell, D. W. Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Investig., 90: 799-809, 1992.
4. Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., and Russell, D. W. Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression. J. Clin. Investig., 92: 903-910, 1993.
5. Wilbert, D. M., Griffin, J. E., and Wilson, J. D. Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocrinol. Metab., 56: 113-120, 1983.
6. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, F. Z., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
7. Wu, A. H., Whittemore, A. S., Kolonel, L. N., John, E. M., Gallagher, R. P., West, D. W., Hankin, J., The, C. Z., Dreon, D. M., and Paffenbarger, R. S., Jr. Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol. Biomark. Prev., 4: 735-741, 1995.
8. Reichardt, J. K., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
9. Makridakis, N., Ross, R. K., Pike, M. C., Chang, P. L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
10. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.
11. Davis, D. L., and Russell, D. W. Unusual length polymorphism in human steroid 5-α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2: 820, 1993.
12. Nam, R. K., Toi, A., Vesprini, D., Ho, M., Chu, W., Harvie, S., Sweet, J., Trachtenberg, J., Jewett, M. A., and Narod, S. A. V89L polymorphism of type-2, 5-α reduclase enzyme gene predicts prostate cancer presence and progression. Urology, 57: 199-205, 2001.
13. Febbo, P. G., Kantoff, P. W., Platz, E. A., Casey, D., Batter, S., Giovannucci, E., Hennekens, C. H., and Stampfer, M. J. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res., 59: 5878-5881, 1999.
14. Pearce, C. L., Makridakis, N. M., Ross, R. K., Pike, M., Kolonel, L. N., Henderson, B. E., and Reichardt, J. K. V. Steroid 5-α reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol. Biomark. Prev., II: 417-418, 2002.
15. Lunn, R. M., Bell, D. A., Mohler, J. L., and Taylor, J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.
16. Yamada, Y., Watanabe, M., Murata, M., Yamanaka, M., Kubota, Y., Ito, H., Katoh, T., Kawamura, J., Yatani, R., and Shiraishi, T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP-17) and steroid 5α-reductase type II (SRD5A2) genes on prostatc-cancer risk among the Japanese population. Int. J. Cancer, 92: 683-686, 2001.
17. Latil, A. G., Azzouzi, R., Cancel, G. S., Guillaume, E. C., Cochan-Priollet, B., Berthon, P. L., and Cussenot, O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer (Phila.), 92: 1130-1137, 2001.
18. Hsing, A. W., Chen, C., Chokkalingam, A. P., Gao, Y. T., Dightman, D. A., Nguyen, H. T., Deng, J., Cheng, J., Sesterhenn, I. A., Mostofi, K., Stanczyk, F. Z., and Reichardt, J. K. V. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomark. Prev., 10: 1077-1082, 2001.
19. Soderstrom, T., Wadelius, M., Andersson, S. O., Johansson, J. E., Johansson, S., Granath, F., and Rane, A. 5α-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics, 12: 307-312, 2002.
20. Margiotti, K., Sangiuolo, F., De Luca, A., Froio, F., Pearce, C. L., Ricci-Barbini, V., Micali, F., Bonafe, M., Franceschi, C., Dallapiccola, B., Novelli, G., and Reichardt, J. K. V. Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients. Dis. Markers, 16: 147-150, 2000.
21. Mononen, N., Ikonen, T., Syrjakoski, K., Matikainen, M., Schleutker, J., Tammela, T. L. J., Koivisto, P. A., and Kallioniemi, O. P. A missense substitution A49T in the steroid 5-α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer, 84: 1344-1347, 2001.
22. Kantoff, P. W., Febbo, P. G., Giovannucci, E., Krithivas, K., Dahl, D. M., Chang, G., Hennekens, C. H., Brown, M., and Stampfer, M. J. A polymorphism of the 5 α-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol. Biomark. Prev., 6: 189-192, 1997.
23. Lau, J., Ioannidis, J. P., and Schmid, C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med., 127: 820-826, 1997.
24. Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., and Chalmers, T. C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med., 327: 248-254, 1992.
25. Ioannidis, J. P., Contopoulos-Ioannidis, D. G., and Lau, J. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. J. Clin. Epidemiol., 52: 281-291, 1999.
26. Ioannidis, J. P., and Lau, J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc. Natl. Acad. Sci. USA, 98: 831-836, 2001.
27. Begg, C. B., and Mazumdar, M. Operating characteristics of a rank correlatiou test for publication bias. Biometrics, 50: 1088-1101, 1994.
28. Shibata, A., Garcia, M. I., Cheng, I., Stamey, T. A., McNeal, J. E., Brooks, J. D., Henderson, S., Yemoto, C. E., and Peehl, D. M. Polymorphisms in the androgen receptor and type II 5 α-reductase genes and prostate cancer prognosis. Prostate, 52: 269-278, 2002.
29. Jaffe, J. M., Malkowicz, S. B., Walker, A. H., MacBride, S., Peschel, R., Tomaszewski, J., Van Arsdalen, K., Wein, A. J., and Rebbeck, T. R. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res., 60: 1626-1630, 2000.
30. Ostrander, E. A., and Stanford, J. L. Genetics of prostate cancer: too many loci, too few genes. Am. J. Hum. Genet., 67: 1367-1375, 2000.
31. Stanford, J. L., and Ostrander, E. A. Familial prostate cancer. Epidemiol. Rev., 23: 19-23, 2001.
32. Ruijter, E., van de Kaa, C., Miller, G., Ruiter, D., Debruyne, F., and Schalken, J. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev., 20: 22-45, 1999.
33. Allen, N. E., Forrest, M. S., and Key, T. J. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentration in men. Cancer Epidemiol. Biomark. Prev., 10: 185-189, 2001.
34. Schatzl, G., Madersbacher, S., Gsur, A., Preyer, M., Haidinger, G., Haitel, A., Vutuc, C., Micksche, M., and Marberger, M. Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate, 52: 130-138, 2002.
35. Hsing, A. W. Hormones and prostate cancer: what's next? Epidemiol. Rev., 23: 42-58, 2001.
36. Vatten, L. J., Ursin, G., Ross, R. K., Stanczyk, F. Z., Lobo, R. A., Harvei, S., and Jellum, E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomark. Prev., 6: 967-969, 1997.
37. Ntais, C., Polycarpou, A., and Ioannidis, J. P. A. Association of CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomark. Prev., 12: 120-126, 2003.
38. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., and Contopoulos-Ioannidis, D. G. Replication validity of genetic association studies. Nat. Genet., 29: 306-309, 2001.
39. Ioannidis, J. P., Trikalinos, T. A., Ntzani, E. E., and Contopoulos-Ioannidis, D. G. Genetic associations in big vs. small studies: an empirical evaluation. Lancet, 361: 567-571, 2003.
40. Ioannidis, J. P. Genetic associations: false or true? Trends Mol. Med., 9: 135-138, 2003.
41. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.
42. Shibata, A., Stamey, T. A., McNeal, J. E., Cheng, I., and Peehl, D. M. Genetic polymorphisms in the androgen receptor and type II 5 α-reductase genes in prostate enlargement. J. Urol., 166: 1560-1564, 2001.
43. Azzouzi, A. R., Cochand-Priollet, B., Mangin, P., Fournier, G., Berthon, P., Latil, A., and Cussenot, O. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. Eur. J. Endocrinol., 147: 479-484, 2002.